Vaxcyte (PCVX) Competitors $35.84 +1.07 (+3.08%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PCVX vs. TEVA, ITCI, GMAB, RDY, ASND, MRNA, VTRS, QGEN, ROIV, and LNTHShould you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Roivant Sciences (ROIV), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Vaxcyte vs. Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Roivant Sciences Lantheus Teva Pharmaceutical Industries (NYSE:TEVA) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends. Is TEVA or PCVX more profitable? Vaxcyte has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Vaxcyte's return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-9.91% 42.46% 6.65% Vaxcyte N/A -23.53%-22.20% Does the MarketBeat Community prefer TEVA or PCVX? Teva Pharmaceutical Industries received 1280 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 78.57% of users gave Vaxcyte an outperform vote while only 67.84% of users gave Teva Pharmaceutical Industries an outperform vote. CompanyUnderperformOutperformTeva Pharmaceutical IndustriesOutperform Votes133567.84% Underperform Votes63332.16% VaxcyteOutperform Votes5578.57% Underperform Votes1521.43% Does the media prefer TEVA or PCVX? In the previous week, Teva Pharmaceutical Industries had 2 more articles in the media than Vaxcyte. MarketBeat recorded 18 mentions for Teva Pharmaceutical Industries and 16 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.26 beat Teva Pharmaceutical Industries' score of 1.23 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 14 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of TEVA or PCVX? 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 3.1% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger earnings & valuation, TEVA or PCVX? Vaxcyte has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.54B1.06-$1.64B-$1.45-10.70VaxcyteN/AN/A-$402.27M-$3.80-9.43 Which has more risk & volatility, TEVA or PCVX? Teva Pharmaceutical Industries has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Do analysts prefer TEVA or PCVX? Teva Pharmaceutical Industries presently has a consensus target price of $23.43, indicating a potential upside of 51.05%. Vaxcyte has a consensus target price of $136.50, indicating a potential upside of 280.86%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts clearly believe Vaxcyte is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 SummaryVaxcyte beats Teva Pharmaceutical Industries on 12 of the 18 factors compared between the two stocks. Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCVX vs. The Competition Export to ExcelMetricVaxcyteBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.62B$3.00B$5.57B$7.82BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-7.7930.4222.4218.48Price / SalesN/A498.92394.10103.91Price / CashN/A168.6838.1834.62Price / Book2.753.206.774.25Net Income-$402.27M-$72.35M$3.22B$248.23M7 Day Performance8.08%3.57%3.26%3.29%1 Month Performance-48.40%0.17%0.02%2.42%1 Year Performance-40.81%-21.21%18.01%5.54% Vaxcyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCVXVaxcyte3.0055 of 5 stars$35.84+3.1%$136.50+280.9%-40.8%$4.62BN/A-7.79160Upcoming EarningsPositive NewsTEVATeva Pharmaceutical Industries3.2593 of 5 stars$13.30-2.6%$23.43+76.2%+10.5%$15.08B$16.54B-9.1736,800Upcoming EarningsAnalyst RevisionPositive NewsITCIIntra-Cellular Therapies0.8812 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560Upcoming EarningsAnalyst ForecastGMABGenmab A/S4.4452 of 5 stars$20.07+0.1%$39.17+95.2%-23.6%$13.28B$21.53B11.531,660Upcoming EarningsAnalyst RevisionRDYDr. Reddy's Laboratories1.8436 of 5 stars$13.68+0.1%$17.00+24.3%-5.3%$11.42B$311.31B21.7824,800Upcoming EarningsASNDAscendis Pharma A/S2.3344 of 5 stars$161.15-2.4%$204.67+27.0%+23.1%$9.83B$363.64M-22.70640Upcoming EarningsPositive NewsMRNAModerna4.3377 of 5 stars$25.13+1.7%$58.70+133.6%-74.1%$9.72B$3.20B-2.713,900Upcoming EarningsVTRSViatris1.8348 of 5 stars$7.57+0.1%$10.50+38.7%-27.2%$9.04B$14.74B-10.2337,000Upcoming EarningsQGENQiagen3.6718 of 5 stars$40.51-0.5%$47.83+18.1%+4.0%$9.01B$1.98B112.806,030Upcoming EarningsAnalyst RevisionNews CoverageROIVRoivant Sciences2.1639 of 5 stars$10.04-1.1%$17.50+74.3%+6.6%$7.16B$122.59M-66.93860LNTHLantheus3.98 of 5 stars$100.62-0.7%$129.43+28.6%+56.8%$6.89B$1.53B16.74700Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies Teva Pharmaceutical Industries Competitors Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Moderna Competitors Viatris Competitors Qiagen Competitors Roivant Sciences Competitors Lantheus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCVX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PCVX Stock Free PCVX Stock Alerts